Psoriatic Arthritis

Risankizumab Submitted for Regulatory Approval to FDA, EMA for Psoriatic Arthritis
April 07, 2021

AbbVie announces the submission of regulatory filings for risankizumab to the FDA and EMA seeking approval for the drug as a treatment for psoriatic arthritis.

IL Inhibitors and TYK2 Blocker Near Approval
January 28, 2021

Safety profiles remain consistent longer-term but cost and accessibility are major challenges for biologics aimed at treating psoriasis.

Ixekizumab demonstrates long-term efficacy
November 04, 2020

Ixekizumab demonstrated long-term efficacy in treating psoriasis and psoriatic arthritis across five years, according to data presented by Eli Lilly at the 29th annual European Academy of Dermatology and Venereology (EADV) Congress.